Floatz logo

Ratg

Myeloid Malignancies

Hackensack Meridian HealthPhase 3Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Myeloid Malignancies cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Prelude Therapeutics
Phase 3BB
Cyclophosphamide
Prelude Therapeutics
Phase 3BB
Inno-206
Prelude Therapeutics
Phase 3BB
FILGRASTIM
Franziska Wachter
Phase 2BB
Fludarabine
First Affiliated Hospital of Zhejiang University
Phase 3BB

View all 14 →

Same molecule, other indications

Ratg is also rated in:

Acute Myelogenous LeukemiaDormant
CCC
Indicative ·
51 / 100
View asset →
Myelodysplastic SyndromeDormant
CCC
Indicative ·
48 / 100
View asset →
Chronic Myelogenous LeukemiaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →